Biblio
Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation. Pediatr Blood Cancer. 2023:e30577.
. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. Transplant Cell Ther. 2021.
Combination Therapy for GVHD Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2015.
A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
Patient-reported treatment response in chronic graft--host disease. Haematologica. 2023.
Pericardial effusion following hematopoietic stem cell transplantation in children: Incidence, risk factors, and outcomes. Pediatr Transplant. 2020:e13748.
. .